Opthea Limited American Depositary Shares
Symbol: OPT (NASDAQ)
0.00
0.00 0.000
Company Description:
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Key Stats
- Today's Open: $
- Today's High: $
- Today's Low: $
- Today's Volume:
- Yesterday Close: $
- Yesterday High: $
- Yesterday Low: $
- Yesterday Volume:
- Last Min Volume:
- Last Min High: $
- Last Min Low: $
- Last Min VWAP: $
Company Profile
- Name: Opthea Limited American Depositary Shares
- Website: https://www.opthea.com
- Listed Date: 2011-06-07
- Location: ,
- Market Status: Active
- CIK Number: 0001815620
- SIC Code:
- SIC description:
- Market Cap: $
- Round Lot: 100
- Outstanding Shares: 153.91M
- Asset Type: ADRC
RECENT FILINGS FOR OPT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-15 | 20-F | View |
| 2025-09-15 | 6-K | View |
| 2025-08-29 | 6-K | View |
| 2025-08-20 | 6-K | View |
| 2025-08-19 | 6-K | View |
| 2025-08-19 | 6-K | View |
| 2025-06-02 | 6-K | View |
| 2025-04-10 | 6-K | View |
| 2025-03-31 | 6-K | View |
| 2025-03-24 | 6-K | View |
| 2025-03-03 | 6-K | View |
| 2025-02-28 | 6-K | View |
| 2025-02-26 | 6-K | View |
| 2025-02-18 | 6-K | View |
| 2025-02-07 | 6-K | View |
| 2025-02-06 | 6-K | View |
| 2025-01-28 | 6-K | View |
| 2025-01-13 | 6-K | View |
| 2025-01-08 | 6-K | View |
| 2025-01-07 | 6-K | View |
Latest News on OPT